What is William Blair's Estimate for APLS Q4 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Monday, October 28th. William Blair analyst L. Hanbury-Brown expects that the company will post earnings per share of $0.23 for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.37) per share.

A number of other research analysts have also recently commented on APLS. Wedbush increased their price target on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a "neutral" rating in a research note on Friday, August 9th. Wells Fargo & Company cut their price target on Apellis Pharmaceuticals from $47.00 to $43.00 and set an "equal weight" rating on the stock in a research note on Tuesday, September 24th. HC Wainwright lowered their price objective on Apellis Pharmaceuticals from $92.00 to $83.00 and set a "buy" rating for the company in a research note on Friday, August 2nd. UBS Group cut their target price on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an "overweight" rating on the stock in a report on Friday, September 13th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $65.41.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS traded up $0.30 on Wednesday, hitting $27.71. The company had a trading volume of 1,655,018 shares, compared to its average volume of 1,686,701. The firm has a 50 day moving average of $32.76 and a two-hundred day moving average of $38.01. The stock has a market capitalization of $3.36 billion, a price-to-earnings ratio of -8.01 and a beta of 0.87. Apellis Pharmaceuticals has a 52 week low of $26.28 and a 52 week high of $73.80. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.03. The firm had revenue of $199.70 million during the quarter, compared to analysts' expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business's revenue for the quarter was up 110.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.02) earnings per share.

Insiders Place Their Bets

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the business's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.80% of the company's stock.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BI Asset Management Fondsmaeglerselskab A S bought a new position in Apellis Pharmaceuticals during the 1st quarter valued at $89,000. nVerses Capital LLC boosted its holdings in Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company's stock worth $107,000 after purchasing an additional 2,100 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock worth $130,000 after purchasing an additional 781 shares in the last quarter. CWM LLC increased its stake in Apellis Pharmaceuticals by 299.9% in the 2nd quarter. CWM LLC now owns 4,151 shares of the company's stock valued at $159,000 after buying an additional 3,113 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Apellis Pharmaceuticals by 1,300.8% in the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company's stock valued at $211,000 after buying an additional 3,330 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).